The Quantellect read.As of Nov 19, 2026, 9 active firms cover BioAge Labs, Inc: 7 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $8.00 to $73.00 (about 9.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $40.78 sits 754% above the current $4.78. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.69 next quarter toward $-2.62 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Buy
Strong Buy00%
Buy778%
Neutral222%
Sell00%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$40.78
+754.0% upside
Average target across 9 active firms as of Nov 19, 2026 vs $4.78 current
Highest Target$73.00
Average Target$40.78
Lowest Target$8.00
Detailed analyst forecasts for BIOA
Showing 1–9 of 9 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 7 of 9 active firms rate BIOA a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BIOA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.69
Range $-0.78 – $-0.58 · 4 analysts · +33% YoY
Next period, 4 analysts expect BioAge Labs, Inc to earn $-0.69 a share (range $-0.78 – $-0.58), versus $-0.52 a year earlier. Full-year consensus is $-2.57, growing to $-2.62 the year after.
REVENUE · NEXT QUARTER
$383.3K
Range $0 – $800.0K · 4 analysts · -86% YoY
Revenue is expected to reach $383.3K (range $0 – $800.0K), -86.2% year-over-year. Full-year consensus is $6.9M, rising to $14.5M next year.
Top analysts covering BioAge Labs, Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BIOA.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #10
Neutral
$12.00+151.3% to target
Overall win rate
64%
+ Follow
#2
Roger Song
Jefferies · Rank #122
Buy
$21.00+339.8% to target
Overall win rate
43%
+ Follow
#3
Joseph Stringer
Needham · Rank #256
Buy
$35.00+633.0% to target
Overall win rate
36%
+ Follow
#4
SS
Samantha Semenkow
Citigroup · Rank #333
Buy
$21.00+339.8% to target
Overall win rate
41%
+ Follow
#5
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$73.00+1428.8% to target
Overall win rate
30%
+ Follow
BIOA stock forecast FAQ
What is BIOA's average 12-month price target?+
The 9 active firms with a live target average $40.78 for BioAge Labs, Inc over the next 12 months, ranging from a $73.00 high to a $8.00 low, as of Nov 19, 2026.
Is BIOA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 9 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BIOA?+
The Street-high target is $73.00 (Piper Sandler), and the Street-low is $8.00 (UBS). The average of all 9 active-firm targets is $40.78.
How many active Wall Street firms cover BIOA?+
9 active firms have a recognized rating on BioAge Labs, Inc as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BIOA?+
Among analysts who currently cover BIOA, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #10). Their current call is Neutral with a $12.00 target.
What is BioAge Labs, Inc's projected EPS for next quarter?+
The consensus estimate is $-0.69 per share (range $-0.78 – $-0.58) across 4 analysts. Full-year EPS is projected at $-2.57, rising to $-2.62 the following year.
How much revenue is BioAge Labs, Inc expected to report next quarter?+
Consensus revenue is $383.3K (range $0 – $800.0K). Full-year revenue is projected at $6.9M, growing to $14.5M next year.
Have analysts been upgrading or downgrading BIOA lately?+
As of Nov 19, 2026, 7 of 9 active firms rate BIOA a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BIOA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.